logo
Plus   Neg
Share
Email

Novartis Joins Global Chagas Disease Coalition

At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis said that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form of heart failure with reduced ejection fraction.

This is the first definitive morbidity and mortality study to assess a potential therapy for cardiac disease in this underserved patient population.

The clinical trial will assess the efficacy and safety of Entresto vs. enalapril and is expected to start within 2019, with the aim of recruiting approximately 900 patients with confirmed Chagas disease in Latin America. The primary endpoint is time to occurrence of a composite of cardiovascular events, including cardiovascular death or first hospitalization due to heart failure.

The definitive study follows an exploratory post hoc analysis from the PARADIGM-HF trial, which suggested that Entresto may have beneficial effects in people with chronic Chagas cardiomyopathy and heart failure with reduced ejection fraction.

At the same time, Novartis is working with stakeholders in endemic countries to co-develop tailored access-to-medicine programs and health system strengthening strategies to help ensure lower-income patients suffering from chronic Chagas cardiomyopathy can benefit from the best available treatment.

Novartis said it is also taking steps to advance research efforts around the disease and is committed to providing mentorship opportunities for scientists from Latin America to help strengthen capacity for relevant research regionally. The Novartis Institute for Tropical Diseases (NITD), the Genomics Institute of the Novartis Research Foundation (GNF) and collaborators have developed a promising portfolio of novel drug candidates for the treatment of kinetoplastid diseases.

The proteasome inhibitor LXE408 was recently advanced as a promising drug candidate for the treatment of visceral leishmaniasis. This novel mechanism of action is also being explored for other indications, including Chagas disease.

In addition, Novartis is partnering with the World Heart Federation to develop an end-to-end roadmap for addressing Chagas disease. The final roadmap is expected to be launched within 2019. In parallel, we are working together with different stakeholders in Latin American countries, such as Argentina and Colombia, to support existing national plans for an integrated care approach to Chagas disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Starbucks Inc. has announced changes to its Starbucks Rewards loyalty program, noting that the revamp will provide its members with more flexibility and choice when they redeem stars at the company's stores. Starting on April 16, all members of the Starbucks Rewards loyalty program will be able to earn and redeem Stars for Rewards immediately after they join the program. Payment processing giant Visa Inc. is seeking a Technical Product Manager with expertise in cryptocurrency and blockchain for its cryptocurrency team. The company has listed a job opening on San Francisco-based recruiting software firm SmartRecruiters to find the manager for Visa Fintech. IBM announced the launch of IBM Blockchain World Wire, a real-time global payments network, aiming to support payments and foreign exchange in more than 50 countries. The network provides real time clearing and settlement using both stable coin backed by U.S. dollars and cryptocurrency.
Follow RTT